| This is the talk page for discussing improvements to the Curia (company) article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
 | This article was nominated for deletion on 7 February 2014. The result of the discussion was no consensus. |
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
Unsourced additions
editThe following were added in these edits. Moved here per WP:PRESERVE. per WP:BURDEN please do not restore without finding reliable sources, checking the content against them, and citing them.
In June 2014, AMRI acquired OsoBio Pharmaceuticals, a large scale CMO specializing in aseptic filling for $110M. This firmly expanded AMRI's reputation as a commercial injectibles CMO.
and
By early 2017, the company had amassed a debt of $600M due to numerous acquisitions. In addition, the Euticals acquisition was proving costly. The company decided to sell itself to two Private Equity firms at a value of nearly $930M. This merger was approved by the AMRI board on June 5th 2017 and is expected to be ratified by the majority of shareholders in the summer of 2017.
-- Jytdog (talk) 23:30, 10 June 2017 (UTC)
- done. Jytdog (talk) 02:45, 11 June 2017 (UTC)
Name change
editAMRI Global is now Curia Global.
The company is referred to as Curia in the text interchangeably, but it is not clearly stated anywhere. (And the page name is now obsolete/outdated.)
Should most of this migrate to a new page "Curia Global", then have this page redirect to Curia Global? Shigekims (talk) 00:20, 16 May 2023 (UTC)